Clinical validation of C 12 FDG as a marker associated with senescence and osteoarthritic phenotypes
Aging Cell · 2024-05 · 23 (5)
DOI: 10.1111/acel.14113 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aging Cell, online erschienen am 06.05.2024. Verfasst von William S Hambright und 20 weiteren Autor:innen. Beteiligte Einrichtung: Center for Regenerative Sports Medicine, Steadman Philippon Research Institute, Vail, Colorado, USA. Hauptthemen laut MEDLINE: Biomarkers, Cellular Senescence, Osteoarthritis, Phenotype. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, Orthopaedic Research and Education Foundation, NIDCR NIH HHS.
Abstract (Originalsprache)
Chronic conditions associated with aging have proven difficult to prevent or treat. Senescence is a cell fate defined by loss of proliferative capacity and the development of a pro‐inflammatory senescence‐associated secretory phenotype comprised of cytokines/chemokines, proteases, and other factors that promotes age‐related diseases. Specifically, an increase in senescent peripheral blood mononuclear cells (PBMCs), including T cells, is associated with conditions like frailty, rheumatoid arthritis, and bone loss. However, it is unknown if the percentage of senescent PBMCs associated with age‐associated orthopedic decline could be used for potential diagnostic or prognostic use in orthopedics. Here, we report senescent cell detection using the fluorescent compound C 12 FDG to quantify PBMCs senescence across a large cohort of healthy and osteoarthritic patients. There is an increase in the percent of circulating C 12 FDG + PBMCs that is commensurate with increases in age and senescence‐related serum biomarkers. Interestingly, C 12 FDG + PBMCs and T cells also were found to be elevated in patients with mild to moderate osteoarthritis, a progressive joint disease that is strongly associated with inflammation. The percent of C 12 FDG + PBMCs and age‐related serum biomarkers were decreased in a small subgroup of study participants taking the senolytic drug fisetin. These results demonstrate quantifiable measurements in a large group of participants that could create a composite score of healthy aging sensitive enough to detect changes following senolytic therapy and may predict age‐related orthopedic decline. Detection of peripheral senescence in PBMCs and subsets using C 12 FDG may be clinically useful for quantifying cellular senescence and determining how and if it plays a pathological role in osteoarthritic progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Regenerative Sports Medicine, Steadman Philippon Research Institute, Vail, Colorado, USA.
- Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Biochemistry and Molecular Biology and Biophysics, Institute on the Biology of Aging and Metabolism, University of Minnesota, Minneapolis, Minnesota, USA.
- Division of General Internal Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
- Orthopaedic Trauma Institute, University of California San Francisco, San Francisco, California, USA.
- The Steadman Clinic, Vail, Colorado, USA.
ORCID-Profile: Victoria R Duke, Heidi Kloser, Aiping Lu, Jair M Espindola Netto, Paul D Robbins, Laura J Niedernhofer, Chelsea S Bahney, Marc Philippon, Johnny Huard
Förderung
- NIAMS NIH HHS
- Orthopaedic Research and Education Foundation
- NIDCR NIH HHS
- Department of Defense Office of Naval Research
- NIA NIH HHS
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
Zitieren
APA
Hambright, W. S., Duke, V. R., Goff, A. D., Goff, A. W., Minas, L. T., Kloser, H., Gao, X., Huard, C., Guo, P., Lu, A., Mitchell, J., Mullen, M., Su, C., Tchkonia, T., Espindola Netto, J. M., Robbins, P. D., Niedernhofer, L. J., Kirkland, J. L., Bahney, C. S., …, & Huard, J. (2024). Clinical validation of C 12 FDG as a marker associated with senescence and osteoarthritic phenotypes. Aging Cell, 23(5). https://doi.org/10.1111/acel.14113
Vancouver
Hambright WS, Duke VR, Goff AD, Goff AW, Minas LT, Kloser H, et al. Clinical validation of C 12 FDG as a marker associated with senescence and osteoarthritic phenotypes. Aging Cell. 2024;23(5). doi:10.1111/acel.14113
BibTeX
@article{Hambright2024,
author = {Hambright, William S and Duke, Victoria R and Goff, Adam D and Goff, Alex W and Minas, Lucas T and Kloser, Heidi and Gao, Xueqin and Huard, Charles and Guo, Ping and Lu, Aiping and Mitchell, John and Mullen, Michael and Su, Charles and Tchkonia, Tamara and Espindola Netto, Jair M and Robbins, Paul D and Niedernhofer, Laura J and Kirkland, James L and Bahney, Chelsea S and Philippon, Marc and Huard, Johnny},
title = {Clinical validation of C 12 FDG as a marker associated with senescence and osteoarthritic phenotypes},
journal = {Aging Cell},
year = {2024},
volume = {23},
number = {5},
doi = {10.1111/acel.14113}
}
EUVIMED